ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,064.20
0.91%
Dow Jones
38,225.66
0.85%
US Dollar vs MXN
16.97203
0.00%
Brent Oil
83.875
0.29%
Bitcoin
59,444.64
0.55%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Adial Pharmaceuticals Inc (ADIL)

  7. Adial Pharmaceuticals Inc (ADIL) Noticias

ADIL Adial Pharmaceuticals Inc

1.83
0.07 (3.98%)
02 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Adial Pharmaceuticals Inc ADIL NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.07 3.98% 1.83 18:08:17
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
1.79 1.7634 1.92 1.79 1.76
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
22/4/202407:30GLOBEAdial Pharmaceuticals Granted Key Patent from the United..
10/4/202407:30GLOBEAdial Pharmaceuticals Announces Peer-Reviewed Publication..
02/4/202407:30GLOBEAdial Pharmaceuticals Reports 2023 Fiscal Year Financial..
01/3/202418:00GLOBEAdial Pharmaceuticals Announces Exercise of Warrants for..
28/2/202408:30GLOBEAdial Pharmaceuticals Awarded New Patent from the United..
14/2/202414:22EDGAR2Form SC 13G - Statement of acquisition of beneficial..
13/2/202408:15GLOBEAdial Pharmaceuticals Awarded New Patent Notice of Allowance..
25/1/202415:30EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
24/1/202423:15EDGAR2Form EFFECT - Notice of Effectiveness
18/1/202415:15EDGAR2Form 8-K - Current report
18/1/202407:30GLOBEAdial Announces Appointment of Tony Goodman as Chief..
16/1/202415:17EDGAR2Form 8-K - Current report
12/1/202415:51EDGAR2Form S-3 - Registration statement under Securities Act of..
20/12/202308:00GLOBEAdial Pharmaceuticals Receives Final Reimbursement Payment..
12/12/202315:36EDGAR2Form S-8 - Securities to be offered to employees in employee..
08/12/202310:08EDGAR2Form DEF 14A - Other definitive proxy statements
29/11/202315:47EDGAR2Form 8-K - Current report
29/11/202315:05GLOBEAdial Pharmaceuticals Regains Compliance with Nasdaq Listing..
28/11/202315:10EDGAR2Form 8-K - Current report
24/11/202308:24EDGAR2Form PRE 14A - Other preliminary proxy statements
20/11/202306:46EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
14/11/202316:02GLOBEAdial Pharmaceuticals Reports Third Quarter 2023 Financial..
08/11/202315:05EDGAR2Form S-1 - General form for registration of securities under..
06/11/202305:14EDGAR2Form 8-K - Current report
31/10/202307:30GLOBEAdial Pharmaceuticals Chief Medical Officer and Key Opinion..
30/10/202316:24EDGAR2Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]:..
30/10/202316:18EDGAR2Form 8-K/A - Current report: [Amend]
30/10/202316:17EDGAR2Form NT 10-Q/A - Notification of inability to timely file..
25/10/202307:00GLOBEAddiction Experts Highlight the Need for..
24/10/202315:48EDGAR2Form 8-K - Current report
24/10/202315:30GLOBEAdial Pharmaceuticals Announces Closing of $4 Million..
20/10/202307:00GLOBEAdial Pharmaceuticals Announces $4 Million Private Placement..
19/10/202309:30GLOBEAdial Pharmaceuticals Awarded Notice of Allowance for Key..
18/10/202307:00GLOBEAdial Pharmaceuticals Wins Frost & Sullivan's 2023 North..
03/10/202307:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/9/202306:00GLOBEAdial Pharmaceuticals to Host a Virtual Key Opinion Leader..
26/9/202320:08EDGAR2Form 8-K - Current report
21/9/202315:10EDGAR2Form 8-K - Current report
11/9/202305:03EDGAR2Form 8-K - Current report
05/9/202307:30GLOBEAdial Pharmaceuticals to Present at the H.C. Wainwright 25th..
28/8/202307:30GLOBEAdial Pharmaceuticals Chief Medical Officer and Key Opinion..
23/8/202307:45EDGAR2Form 8-K - Current report
23/8/202307:30GLOBEAdial Pharmaceuticals Regains Compliance with Nasdaq Listing..
21/8/202307:46EDGAR2Form 8-K - Current report
21/8/202307:30GLOBEAdial Pharmaceuticals Reports Second Quarter 2023 Financial..
21/8/202307:21EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
18/8/202316:05EDGAR2Form 8-K - Current report
15/8/202305:01EDGAR2Form NT 10-Q - Notification of inability to timely file Form..
04/8/202307:30EDGAR2Form 8-K - Current report
04/8/202307:30GLOBEAdial Pharmaceuticals Announces Reverse Stock Split to..

Su Consulta Reciente

NASDAQ
ADIL
Adial Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados